Research opportunities for children and young people with JIA

Juvenile idiopathic arthritis (JIA)

There are research studies taking place in your area.

You/your child may be able to take part.

This leaflet has information on research studies taking place across the United Kingdom (UK) which children and young people with JIA can take part in.

Only brief summaries are provided, and not all inclusion and exclusion criteria are listed. If you/your child are interested in taking part in any of the research studies, please speak to your rheumatology team!

This document can be downloaded from: www.liverpool.ac.uk/eatc-for-children/research/workstreams/jia
Observational research studies are where researchers look at groups of people with similar health conditions or treatments and collect information about them and their condition(s).

Some studies have an acronym (e.g. BCRD). For each study, there is a description, the name of the researcher looking after the study, and a website link (if there is one).

**BCRD**
A study looking at how well biologics work, and the long-term safety of biologics in children.
Professor Kimme Hyrich
www.bcrdstudy.org

**BSPAR-ECS**
A study looking at how well etanercept works, and the long-term safety of etanercept in children.
Professor Kimme Hyrich
www.rheumatology.org.uk/Knowledge/Registers/Juvenile-Idiopathic-Arthritis-register

**CHARMS**
A large study aiming to predict how children with JIA respond to different medicines.
Professor Lucy Wedderburn
www.sparkscharms.org.uk

**CLUSTER**
A new collaborative project bringing together data from many JIA and JIA uveitis studies to design ways to predict treatment response and disease outcomes.
Professor Lucy Wedderburn
For more information, email l.weddernburn@ucl.ac.uk

If you are interested in a study, mention it to your rheumatology team!
Interventional research studies are where people are assigned to groups that receive one or more interventions or treatments (e.g. a medicine, an exercise, an online resource), or no intervention at all. Researchers then look at the effect of the intervention or treatment on health and wellbeing.

For each study, there is a description, the locations where the study is taking place, the name of the researcher looking after the study, and a website link (if there is one).

**Sarilumab in systemic JIA**
BRISTOL, LEEDS, LIVERPOOL, LONDON

A study attempting to find the right dose of a new biological medicine called sarilumab in children and young people with active systemic JIA.

Professor Athimalaipet Ramanan
www.clinicaltrials.gov/ct2/show/NCT02991469

**Sarilumab in polyarticular JIA**
BRISTOL, LIVERPOOL, LONDON (GOSH/UCLH)

A study attempting to find the right dose of a new biological medicine called sarilumab in children and young people with polyarticular JIA.

Professor Athimalaipet Ramanan
www.clinicaltrials.gov/show/NCT02776735

**Emapalumab in MAS**
LONDON (GOSH)

A study looking at how well a new biological medicine called emapalumab works in children and young people with macrophage activation syndrome (MAS), which may develop on the background of systemic JIA.

Professor Paul Brogan & Dr Despina Eleftheriou
www.clinicaltrials.gov/ct2/show/NCT03311854

**Baricitinib in polyarticular JIA**
BRISTOL, LONDON (GOSH/UCLH), SHEFFIELD

A study looking at how well baricitinib, an oral Janus Kinase (JAK) inhibitor medicine, works for children and young people with polyarticular JIA.

Professor Athimalaipet Ramanan
www.clinicaltrials.gov/ct2/show/NCT03773965

***** THE FOLLOWING STUDIES ARE ABOUT TO OPEN. *****

**Tofacitinib in systemic JIA**
CAMBRIDGE, OXFORD

A study looking at how well tofacitinib, an oral Janus Kinase (JAK) inhibitor medicine, works for children and young people with active systemic JIA who don’t respond to methotrexate.

Dr Kate Armon

**Baricitinib in uveitis**
BRISTOL, LIVERPOOL, LONDON (GOSH)

A study looking at how well baricitinib, an oral Janus Kinase (JAK) inhibitor medicine, works for children and young people with JIA-associated uveitis.

Professor Athimalaipet Ramanan
Let us know what you think about our leaflet, and help us to improve it by completing our quick survey:


If you are interested in a study, mention it to your rheumatology team!

ADJUST stands for ‘Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial’. ADJUST will begin to identify children and young people in the UK by early summer 2019. Children and young people (2 years and older) with a diagnosis of juvenile idiopathic arthritis-associated uveitis who are currently taking adalimumab (Humira®) and are interested in stopping their medication may be eligible for this 12-month study. The hospitals which will be identifying children and young people are shown below, alongside the lead researcher(s) at each hospital.

BRISTOL, LIVERPOOL, LONDON (GOSH), NEWCASTLE, SHEFFIELD, SOUTHAMPTON

www.clinicaltrials.gov/ct2/show/NCT03816397

Professor Athimalaipet Ramanan

ADJUST@ucsf.edu